■ INTEGRATE-PAIN, a transatlantic US-European interaction in pain research between the NIH HEAL InitiativeSM and the IMI-PainCare consortium ■

Innovations in pain management are needed to reduce the suffering of many people who cannot be treated adequately with current therapies. As lack of effective and safe pain management is a societal problem, it is in the interests of all stakeholders to interact closely to improve the situation. The NIH HEAL and IMI-PainCare teams realized the congruency of their approaches, which strongly supports that valuable synergies will arise from a transatlantic consensus. Dedicated to improving the understanding, management, and treatment of pain, both teams have prioritized common opportunities in preclinical and clinical research, ultimately accelerating the discovery and development of new non-addictive treatments and improving the management of pain.

Together, we established INTEGRATE-Pain, the “IMI-NIH Transatlantic Emphasis Group on Research And Translation-to-care Efforts for Pain”. Our objectives are transatlantic knowledge sharing, harmonizing of standards, combination of infrastructures, coordination of data collection to improve the statistical power of data interpretation in future meta-analyses, and joint dissemination.

On August 5th and 6th 2020, INTEGRATE-Pain will have virtual meetings, originally planned as personal appointments during the IASP 2020 World Pain Congress.

The NIH HEAL Initiative:
The Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Almost every NIH Institute and Center is accelerating research to address this public health emergency from all angles.

The initiative is funding hundreds of projects nationwide. Researchers are taking a variety of approaches to tackle the opioid epidemic through:
  • Understanding, managing, and treating pain
  • Improving treatment for opioid misuse and addiction
More information on the NIH HEAL Initiative: https://heal.nih.gov/.

■ Topical workshop at IASP, 2021 ■


We are delighted that our proposal for a topical workshop “Development of biomarkers for pain: recent advances from research consortia in Europe, U.S.A. and Japan” has been selected for inclusion in the program of the IASP World congress on Pain.
Together with speakers from the U.S.A. and Japan, we will be talking about the need for biomarkers in pain R&D and clinical practice, ultimately to develop novel approaches and for a paradigm change in pain management.
Recent progress of IMI-PainCare and current pain R&D initiatives in U.S.A. and Japan will be presented in generating a comprehensive set of tools which will expand knowledge about pain targets and pathways.
In addition, we will explain efforts to validate biomarkers which will enable stratification of pain patients to allow more individualized treatments, and discover innovative and objective methods for evaluating the success of pain therapies in real-world clinical practice and in clinical trials (Phase II and III).
Looking forward to meeting you at the congress to discuss and invite you to support and synergize with these initiatives.
For more details see https://iaspworldcongress.pathable.co/meetings/DQEhT9wx5Wt2QXdJJ#/

■ General Assembly, 2020 ■

Eli Lilly, UK, thankfully hosted the IMI-PainCare General Assembly 2020. The meeting offered an exciting platform to present progress achieved in the project over the last period. While the joint sessions resulted in inspiring discussions and cross-fertilizations between the sub-projects PROMPT, BIOPAIN and TRiPP, the F2F meetings of the sub-projects set their focus on their specific topics.